Danielle Zakon

Medical Oncologist. Clinical Research Fellow at MD Anderson Cancer Center #bcsm

[Paolo Tarantino @PTarantinoMD]

Second ADC Press Release of the day:
the Trop2 ADC sacituzumab govitecan + pembro improved PFS vs. chemo + pembro for patients with untreated PD-L1+ mTNBC. New 1L standard of care coming. https://t.co/Tr83WJDlFn

[OncoAlert @OncoAlert]

NEWS FROM INDUSTRY
Source AstraZeneca

https://t.co/0ie3lchUKm

The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically significant and clinically meaningful improvement in PFS 🆚 the current 1st-line standard regimen of taxane, trastuzumab, and pertuzumab (THP). This is the first trial in over a decade to demonstrate superior efficacy across a broad HER2-positive metastatic population in the 1st-line setting. While OS data remain immature, early trends favor the Enhertu combination.

Ping OncoAlert Breast #Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

[Paolo Tarantino @PTarantinoMD]

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.

Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

[VIRGINIA KAKLAMANI @VKaklamani]

My take aways from #sabcs24: anthra beneficial for RS>31; imlunestrant active as single agent unclear what combo data means; Pablo gives excellent benefit in triple pos bc; please don’t use MRD ; brca + bc pts have benefit from rrbm; and tons of important data on local therapy.

[GBECAM @GBECAMConnect]

Part of the @Gbecamconnect team at #SABCS24! 🇧🇷🎉 We’re returning to Brazil with fresh insights and ready to elevate breast cancer care and research for our patients in Brazil! 🇧🇷💪📊 Let’s keep making progress together! 🌟🎗️ #BreastCancer #SABCS @SABCSSanAntonio

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this new study published in @ESMO_Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆
🔓https://t.co/qdZkuU1DnB
✍️@PTarantinoMD @EMittendorfMD @TariKingMD @stolaney1 @NabihahTayob @nlinmd #AnaGarridoCastro #BreastCancer

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Clinical outcomes of e-TNBC after neoadjuvant chemotherapy according to HER2-low status
👉her 2 low e tnbc has higher nodal involvement
👉No diff in pCR
👉No diff in RFS, DRFS or OS
👉study conducted before arrival of keynote 522
@ESMO_Open @stolaney1
https://t.co/W3g9kjGRVo

[CA: A Cancer Journal for Clinicians @CACancerJournal]

This #PrecisionMedicine review by @VivekSubbiah et al delves into the expansive landscape of tissue-agnostic targets and drugs. Read about expanded target population, incorporating genomic testing in daily practice, and less toxic managements.

More at:
https://t.co/Y8KMxoMPkG

[Yakup Ergün @dr_yakupergun]

Different dosage forms of GnRHa with ET in premenopausal HR+ BC

💥In this retrospective study of 950 patients, the three-month GnRHa regimen was found to be as effective and safe as the one-month regimen for ovarian function suppression

@JNCI_Now
https://t.co/o1aZ0aXa7N

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

#cancer is increasing worldwide and around 50% of cancers can be prevented! Here are 12 ways to reduce the risk of cancer by @EuropeanCommiss
@myESMO @ASCO @IARCWHO @mybsmo @BIGagainstBC @JulesBordet @ULBRecherche @H.U.B #screening #lifechanges

[Dr Sarah Sammons @drsarahsam]

“Among pts with RCB-0/1, over half (21/38 [55.3%]) of all events were CNS recurrences, with 13/22 (59.1%) in the pembro group and 8/16 (50.0%) in the placebo group.”

Brain Mets account for 60% of events in RCB0/1 pts on Keynote 522. We would need to predict to prevent. #bcsm

[Erman Akkus @Erman_Akkus]

📣Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
@Annals_Oncology @myESMO

➡️ctDNA
➡️For now, plasma should be used. But in future, disease-specific sample may be used (urine, bile)
➡️In metastatic setting, used to evaluate the response. In earlier disease settings, it may be game changer to follow MRD and may lead treatment choice/intensity.
➡️Should be measured at multiple time points at regular intervals, incorporating with imaging
➡️Should be measured 4 weeks after surgery
➡️Solely or with imaging? Or when imaging fails to give definitive result? Head to head comparison between imaging and ctDNA would be ideal
➡️Technology: Detection of ctDNA mutations, methylation, tumor tissue-informed approach: standardizing is challenging
➡️Negative in baseline? Brain-only disease? Changes according to the type of therapy?
➡️In fact, clinical trials have started to incorporate ctDNA
➡️Regulatory issues

✅Authors suggested a useful trial design👇

👉https://t.co/zTXkS86kVE

@mgoudaMD @curijoey @VivekSubbiah @MDAndersonNews @ESMO_Open @EMA_News @FDAOncology @DenizCanGuven1 @DrHongchengZhu @pawel_sobczuk @ekocakavuk

#cancer #Oncology #treatment #MedX

[DocWire News @mydocwire]

The @OncBrothers—Rahul Gosain, MD, and Rohit Gosain, MD,—are joined by Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, to discuss the HER2CLIMB-02 study presented at #SABCS23.
Watch Now: https://t.co/TCeiQFtgOT

[Paolo Tarantino @PTarantinoMD]

Reading good review articles can shape ideas, help connecting the dots and understanding what’s coming ahead in science.

Here’s 10 review articles that helped me shape my views on breast oncology and drug development:

[Jason A. Mouabbi MD @JAMouabbi]

Exciting news from @OncJournal following the impactful #SABCS23! 🌟
Our recent @MDAndersonNews publication addresses a pivotal question: In the era of #ADC, where patients must have received ≥ 1️⃣ prior #chemotherapy agent, should #capecitabine or a #taxane be utilized for #ILC patients❓🤨

Our compelling findings strongly advocate for #capecitabine’s superiority: 8.8 vs 5.0 months
HR 0.63, P < .001 🙌🏻

@DrDebuTripathy #Rachel_Layman

[Paolo Tarantino @PTarantinoMD]

10 days to #SABCS23, 10 abstracts to keep an eye on. They include practice changing studies, highly awaited updates, important biomarker analyses, &amp; RWD, among others. Not an easy selection: many more impactful studies will be presented. Full program here: https://t.co/kh5bunwhWK

[VIRGINIA KAKLAMANI @VKaklamani]

FDA approved capi but only for patients with AKT pathway altered tumors. Interesting. #bcsm. Awaiting for more data from ⁦@SABCSSanAntonio⁩ #sabcs23

[JAMA Oncology @JAMAOnc]

This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality. https://t.co/XZ4bYUIlbB

[Sara Tolaney @stolaney1]

TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo

63% w/1L prior chemo
~80% w/prior cdk 4/6i

PFS 6.9 vs 4.9 mo, HR 0.63, p&lt;0.0001
ORR 36.4% vs 22.9%

Fewer grade &gt;=3 AEs w/Dato-DXd c/w TPC
50% Stomatitis,3% ILD

@OncoAlert #bcsm #ESMO23 @dradityabardia

[Paolo Tarantino @PTarantinoMD]

More (impressive) data on the intracranial activity of T-DXd. Real-world cohort from Japan, including 104 patients with HER2+ MBC, of which 90 with active brain mets and 19 with LMD. Consistently with TUXEDO-1, IC-ORR was 63%, IC-PFS was 16 months. #bcsm https://t.co/lcjU2GNUDt